Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy

Kavitha Kongara, John Paul Chambers Animal Welfare Science and Bioethics Centre, School of Veterinary Science, Massey University, Palmerston North, New Zealand Abstract: Robenacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID) of coxib class developed for the control of inflammation and pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kongara K, Chambers JP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	robenacoxib preclinical pharmacology clinical studies analgesia tolerability. Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/989ca13b7e5549519c196cfc43023644
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:989ca13b7e5549519c196cfc43023644
record_format	dspace
spelling	oai:doaj.org-article:989ca13b7e5549519c196cfc430236442021-12-02T04:08:47ZRobenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy2230-2034https://doaj.org/article/989ca13b7e5549519c196cfc430236442018-08-01T00:00:00Zhttps://www.dovepress.com/robenacoxib-in-the-treatment-of-pain-in-cats-and-dogs-safety-efficacy--peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034Kavitha Kongara, John Paul Chambers Animal Welfare Science and Bioethics Centre, School of Veterinary Science, Massey University, Palmerston North, New Zealand Abstract: Robenacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID) of coxib class developed for the control of inflammation and pain in dogs and cats. It shows high selectivity for the cyclooxygenase-2 (COX-2) enzyme in rats, cats, and dogs. Robenacoxib is available in both injectable and tablet formulations. This review initially focuses on the preclinical pharmacology of robenacoxib in rats that includes its high affinity for COX-2 enzyme and weaker and rapidly reversible binding for COX-1 enzyme in in vitro and ex vivo models of inflammation and its pharmacokinetics in the blood and inflammatory exudate, selective tissue distribution, and safety. These basic pharmacological profiles highlight the suitability of robenacoxib for use in target species, such as cats and dogs. Since the level of expression and activity of COX enzymes is species specific, COX-2-selective inhibition and the resultant effects of coxibs must be studied in target species. The pharmacological and toxicological profiles of robenacoxib in cats and dogs have been discussed prior to reviewing its clinical efficacy and safety. Large, multicenter field trials conducted in cats and dogs demonstrated the noninferior efficacy and safety of robenacoxib compared with noncoxib NSAIDs used in dogs and cats. These trials investigated the efficacy of robenacoxib against various acute and chronic painful conditions. Robenacoxib produced superior efficacy to placebo and COX-2 preferential inhibitors in postsurgical cats. The tissue-selective anti-inflammatory activity of robenacoxib has been demonstrated in dogs with osteoarthritis. Robenacoxib has also been shown to be safe in healthy dogs and cats receiving antihypertensive drugs and loop diuretics that could cause renal injury. The developmental objective of coxibs, comparable efficacy but superior safety to less selective/nonselective NSAIDs, is well established with robenacoxib in preclinical studies. More studies need to be conducted to fully explore the benefits of robenacoxib in clinical subjects. Keywords: robenacoxib, preclinical pharmacology, clinical studies, analgesia, tolerabilityKongara KChambers JPDove Medical Pressarticlerobenacoxibpreclinical pharmacologyclinical studiesanalgesiatolerability.Veterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol Volume 9, Pp 53-61 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	robenacoxib preclinical pharmacology clinical studies analgesia tolerability. Veterinary medicine SF600-1100
spellingShingle	robenacoxib preclinical pharmacology clinical studies analgesia tolerability. Veterinary medicine SF600-1100 Kongara K Chambers JP Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
description	Kavitha Kongara, John Paul Chambers Animal Welfare Science and Bioethics Centre, School of Veterinary Science, Massey University, Palmerston North, New Zealand Abstract: Robenacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID) of coxib class developed for the control of inflammation and pain in dogs and cats. It shows high selectivity for the cyclooxygenase-2 (COX-2) enzyme in rats, cats, and dogs. Robenacoxib is available in both injectable and tablet formulations. This review initially focuses on the preclinical pharmacology of robenacoxib in rats that includes its high affinity for COX-2 enzyme and weaker and rapidly reversible binding for COX-1 enzyme in in vitro and ex vivo models of inflammation and its pharmacokinetics in the blood and inflammatory exudate, selective tissue distribution, and safety. These basic pharmacological profiles highlight the suitability of robenacoxib for use in target species, such as cats and dogs. Since the level of expression and activity of COX enzymes is species specific, COX-2-selective inhibition and the resultant effects of coxibs must be studied in target species. The pharmacological and toxicological profiles of robenacoxib in cats and dogs have been discussed prior to reviewing its clinical efficacy and safety. Large, multicenter field trials conducted in cats and dogs demonstrated the noninferior efficacy and safety of robenacoxib compared with noncoxib NSAIDs used in dogs and cats. These trials investigated the efficacy of robenacoxib against various acute and chronic painful conditions. Robenacoxib produced superior efficacy to placebo and COX-2 preferential inhibitors in postsurgical cats. The tissue-selective anti-inflammatory activity of robenacoxib has been demonstrated in dogs with osteoarthritis. Robenacoxib has also been shown to be safe in healthy dogs and cats receiving antihypertensive drugs and loop diuretics that could cause renal injury. The developmental objective of coxibs, comparable efficacy but superior safety to less selective/nonselective NSAIDs, is well established with robenacoxib in preclinical studies. More studies need to be conducted to fully explore the benefits of robenacoxib in clinical subjects. Keywords: robenacoxib, preclinical pharmacology, clinical studies, analgesia, tolerability
format	article
author	Kongara K Chambers JP
author_facet	Kongara K Chambers JP
author_sort	Kongara K
title	Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
title_short	Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
title_full	Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
title_fullStr	Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
title_full_unstemmed	Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
title_sort	robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/989ca13b7e5549519c196cfc43023644
work_keys_str_mv	AT kongarak robenacoxibinthetreatmentofpainincatsanddogssafetyefficacyandplaceintherapy AT chambersjp robenacoxibinthetreatmentofpainincatsanddogssafetyefficacyandplaceintherapy
_version_	1718401447267139584

Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy

Ejemplares similares